Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | ECHELON-2 trial updates and the role of transplant in CD30-positive PTCL

Swaminathan Iyer • 10 Jun 2022
EHA 2022
Lymphoma Peripheral T-Cell Lymphoma Rare Diseases Antibodies Brentuximab vedotin Cyclophosphamide Doxorubicin Prednisone Vincristine
ECHELON-2

Swaminathan Iyer, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shares some updates from the ECHELON-2 trial (NCT01777152) comparing the use of brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (BV-CHP) with standard-of-care cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for the treatment of patients with CD30-positive peripheral T-cell lymphoma (PTCL). Dr Iyer first highlights recent updates from this trial and then goes on to discuss the value of upfront stem cell transplantation in these patients. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

CRISPR, SEAGEN, MERCK, RHIZEN, ACROTECH, LEGEND, INNATE

More from Swaminathan Iyer

3:17
PET imaging to predict treatment outcomes: follow-up from the ECHELON-2 trial
Swaminathan Iyer • 11 Dec 2023
2:39
The significance of CD30 in the response to brentuximab vedotin for patients with T-cell lymphoma
Swaminathan Iyer • 11 Dec 2023
5:32
A machine learning model to analyze histopathological tissue in DLBCL
Swaminathan Iyer • 11 Dec 2023
2:57
Lacutamab, an anti-KIR3DL2 monoclonal antibody, in the treatment of R/R PTCL
Swaminathan Iyer • 11 Dec 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals